In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...

That Ozempic (or Wegovy, the name by which the weight-loss version of the drug semaglutide is marketed) should have proliferated in an industry that has always venerated thinness will hardly come as a ...

Semaglutide belongs to a class of prescription medications that mimic a hormone your body naturally produces after you eat. This hormone helps your pancreas make insulin, which lowers your blood sugar ...

An emerging market for compounded weight loss injections that mimic brand-name drugs such as Ozempic, Wegovy, Mounjaro and ...

BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...

The Senate Committee on Health, Education, Labor and Pensions held a hearing on Tuesday, to discuss Novo Nordisk lowering ...

Novo Nordisk CEO Lars Fruergaard Jørgensen faced Senate scrutiny over the high prices of Wegovy and Ozempic as U.S. demand ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Novo Nordisk ...

A new study suggests semaglutide drugs like Ozempic, used for type 2 diabetes, may lower the risk of opioid overdose in ...

Novo Nordisk CEO Lars Fruergaard Jorgensen testified before the Senate Health, Education, Labor and Pensions Committee hearing in ...

Patients on semaglutide, the active ingredient in Ozempic and the weight-loss drug Wegovy, were less than half as likely to overdose.

On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard ...